{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:51Z","timestamp":1787003631786,"version":"build-2736575974"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau","award":["2017KJGG0052"],"award-info":[{"award-number":["2017KJGG0052"]}]},{"name":"Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau","award":["2017KJGG0052"],"award-info":[{"award-number":["2017KJGG0052"]}]},{"name":"Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau","award":["2017KJGG0052"],"award-info":[{"award-number":["2017KJGG0052"]}]},{"name":"Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau","award":["2017KJGG0052"],"award-info":[{"award-number":["2017KJGG0052"]}]},{"name":"Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital","award":["201704"],"award-info":[{"award-number":["201704"]}]},{"name":"Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital","award":["201704"],"award-info":[{"award-number":["201704"]}]},{"name":"Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital","award":["201704"],"award-info":[{"award-number":["201704"]}]},{"name":"Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital","award":["201704"],"award-info":[{"award-number":["201704"]}]},{"name":"Lanzhou City Talent Innovation and Entrepreneurship Project","award":["2019-RC-37"],"award-info":[{"award-number":["2019-RC-37"]}]},{"name":"Lanzhou City Talent Innovation and Entrepreneurship Project","award":["2019-RC-37"],"award-info":[{"award-number":["2019-RC-37"]}]},{"name":"Lanzhou City Talent Innovation and Entrepreneurship Project","award":["2019-RC-37"],"award-info":[{"award-number":["2019-RC-37"]}]},{"name":"Lanzhou City Talent Innovation and Entrepreneurship Project","award":["2019-RC-37"],"award-info":[{"award-number":["2019-RC-37"]}]},{"name":"The Major Scientific Research Project and Key Medical Technology Problem-Solving Project of 2022 China Medical Education Association","award":["2022KTZ007"],"award-info":[{"award-number":["2022KTZ007"]}]},{"name":"The Major Scientific Research Project and Key Medical Technology Problem-Solving Project of 2022 China Medical Education Association","award":["2022KTZ007"],"award-info":[{"award-number":["2022KTZ007"]}]},{"name":"Natural Science Foundations Project of Gansu Province","award":["23JRRM0747"],"award-info":[{"award-number":["23JRRM0747"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04037-w","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T03:37:33Z","timestamp":1749181053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel efferocytosis-related gene signature for predicting prognosis and therapeutic response in bladder cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Weitao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongnuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"4037_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4037_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European association of urology guidelines on Non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in Situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"4037_CR3","doi-asserted-by":"crossref","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u2009\u2013\u2009465; discussion 475\u2013477 (2006).","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"4037_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier, B. P., Hollander, M. P., van Rhijn, B. W., Kiemeney, L. A. & Witjes, J. A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur. Urol. 45, 292\u2013296 (2004).","journal-title":"Eur. Urol."},{"key":"4037_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","volume":"117","author":"M Moschini","year":"2016","unstructured":"Moschini, M. et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int. 117, 604\u2013610 (2016).","journal-title":"BJU Int."},{"key":"4037_CR6","first-page":"749","volume":"57","author":"J Dobruch","year":"2021","unstructured":"Dobruch, J. & Oszczud\u0142owski, M. Bladder cancer: current challenges and future directions. Med. (Kaunas Lithuania). 57, 749 (2021).","journal-title":"Med. (Kaunas Lithuania)"},{"key":"4037_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/jpm13050756","volume":"13","author":"SK Mohanty","year":"2023","unstructured":"Mohanty, S. K., Lobo, A., Mishra, S. K. & Cheng, L. Precision medicine in bladder cancer: present challenges and future directions. J. Pers. Med. 13, 756 (2023).","journal-title":"J. Pers. Med."},{"key":"4037_CR8","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. EMT- and stroma-related gene expression and resistance to PD-1 Blockade in urothelial cancer. Nat. Commun. 9, 3503 (2018).","journal-title":"Nat. Commun."},{"key":"4037_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl, N. et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur. Urol. 75, 707\u2013711 (2019).","journal-title":"Eur. Urol."},{"key":"4037_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.cytogfr.2022.01.002","volume":"63","author":"S Dutta","year":"2022","unstructured":"Dutta, S., Mukherjee, A. & Nongthomba, U. Before the cytokine storm: boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications. Cytokine Growth Factor. Rev. 63, 108\u2013118 (2022).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"4037_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fimmu.2011.00057","volume":"2","author":"D Korns","year":"2011","unstructured":"Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M. & Bratton, D. L. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2, 57 (2011).","journal-title":"Front. Immunol."},{"key":"4037_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.immuni.2019.04.018","volume":"50","author":"S Morioka","year":"2019","unstructured":"Morioka, S., Mauer\u00f6der, C. & Ravichandran, K. S. Living on the edge: efferocytosis at the interface of homeostasis and pathology. Immunity 50, 1149\u20131162 (2019).","journal-title":"Immunity"},{"key":"4037_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","volume":"21","author":"P Mehrotra","year":"2022","unstructured":"Mehrotra, P. & Ravichandran, K. S. Drugging the efferocytosis process: concepts and opportunities. Nat. Rev. Drug Discov. 21, 601\u2013620 (2022).","journal-title":"Nat. Rev. Drug Discov"},{"key":"4037_CR14","doi-asserted-by":"publisher","first-page":"e002548","DOI":"10.1136\/jitc-2021-002548","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. S100A4 enhances protumor macrophage polarization by control of PPAR-\u03b3-dependent induction of fatty acid oxidation. J. Immunother Cancer. 9, e002548 (2021).","journal-title":"J. Immunother Cancer"},{"key":"4037_CR15","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam, A. et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 233, 6425\u20136440 (2018).","journal-title":"J. Cell. Physiol."},{"key":"4037_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.canlet.2020.08.020","volume":"493","author":"L Ma","year":"2020","unstructured":"Ma, L. et al. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression. Cancer Lett. 493, 266\u2013283 (2020).","journal-title":"Cancer Lett."},{"key":"4037_CR17","doi-asserted-by":"publisher","first-page":"25737","DOI":"10.1074\/jbc.M114.570838","volume":"289","author":"KQ Nguyen","year":"2014","unstructured":"Nguyen, K. Q. et al. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. J. Biol. Chem. 289, 25737\u201325749 (2014).","journal-title":"J. Biol. Chem."},{"key":"4037_CR18","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/s41467-024-46735-5","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng, M. et al. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat. Commun. 15, 2818 (2024).","journal-title":"Nat. Commun."},{"key":"4037_CR19","doi-asserted-by":"publisher","first-page":"110735","DOI":"10.1016\/j.epsr.2024.110735","volume":"235","author":"S Giannelos","year":"2024","unstructured":"Giannelos, S., Bellizio, F., Strbac, G. & Zhang, T. Machine learning approaches for predictions of CO2 emissions in the Building sector. Electr. Power Syst. Res. 235, 110735 (2024).","journal-title":"Electr. Power Syst. Res."},{"key":"4037_CR20","doi-asserted-by":"crossref","unstructured":"Pereira, A. G., Barbosa, G. F., Filho, M. G., Shiki, S. B. & da Silva, A. L. Quality control in Extrusion-Based additive manufacturing: A review of machine learning approaches. IEEE Trans. Cybern (2025).","DOI":"10.1109\/TCYB.2025.3558515"},{"key":"4037_CR21","doi-asserted-by":"publisher","first-page":"13508","DOI":"10.1038\/s41598-025-94586-x","volume":"15","author":"C Cetinkaya","year":"2025","unstructured":"Cetinkaya, C. et al. Artificial intelligence-empowered functional design of semi-transparent optoelectronic and photonic devices via deep Q-learning. Sci. Rep. 15, 13508 (2025).","journal-title":"Sci. Rep."},{"key":"4037_CR22","doi-asserted-by":"publisher","first-page":"e3001165","DOI":"10.1371\/journal.pbio.3001165","volume":"19","author":"PE Bourne","year":"2021","unstructured":"Bourne, P. E. Is bioinformatics dead. PLoS Biol. 19, e3001165 (2021).","journal-title":"PLoS Biol."},{"key":"4037_CR23","doi-asserted-by":"publisher","first-page":"22552","DOI":"10.1038\/s41598-024-73422-8","volume":"14","author":"S Guo","year":"2024","unstructured":"Guo, S., Su, Q., Yang, Z. & Mo, W. Development and validation of a novel liquid-liquid phase separation gene signature for bladder cancer. Sci. Rep. 14, 22552 (2024).","journal-title":"Sci. Rep."},{"key":"4037_CR24","doi-asserted-by":"publisher","first-page":"1453448","DOI":"10.3389\/fcell.2024.1453448","volume":"12","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Integrating oxidative-stress biomarkers into a precision oncology risk-stratification model for bladder cancer prognosis and therapy. Front. Cell. Dev. Biol. 12, 1453448 (2024).","journal-title":"Front. Cell. Dev. Biol."},{"key":"4037_CR25","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"4037_CR26","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00011-024-01938-w","volume":"73","author":"F Zhong","year":"2024","unstructured":"Zhong, F. et al. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia. Inflamm. Res. 73, 1889\u20131902 (2024).","journal-title":"Inflamm. Res."},{"key":"4037_CR27","doi-asserted-by":"publisher","first-page":"1295891","DOI":"10.3389\/fcell.2023.1295891","volume":"11","author":"M Gao","year":"2023","unstructured":"Gao, M. et al. Identification of efferocytosis-related subtypes in gliomas and elucidating their characteristics and clinical significance. Front. Cell. Dev. Biol. 11, 1295891 (2023).","journal-title":"Front. Cell. Dev. Biol."},{"key":"4037_CR28","doi-asserted-by":"publisher","first-page":"14226","DOI":"10.1038\/s41598-025-99133-2","volume":"15","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. A signature based on efferocytosis-related genes for the evaluation of prognosis and the tumour microenvironment in gastric cancer. Sci. Rep. 15, 14226 (2025).","journal-title":"Sci. Rep."},{"key":"4037_CR29","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"4037_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"4037_CR31","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"4037_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.drudis.2017.01.005","volume":"22","author":"A Giuliani","year":"2017","unstructured":"Giuliani, A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov Today. 22, 1069\u20131076 (2017).","journal-title":"Drug Discov Today"},{"key":"4037_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"key":"4037_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"4037_CR35","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"4037_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"4037_CR37","doi-asserted-by":"publisher","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","volume":"224","author":"Gene Ontology Consortium","year":"2023","unstructured":"Gene Ontology Consortium. The gene ontology knowledgebase in 2023. Genetics 224, iyad031 (2023).","journal-title":"Genetics"},{"key":"4037_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pro.4218","volume":"31","author":"PD Thomas","year":"2022","unstructured":"Thomas, P. D. et al. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 31, 8\u201322 (2022).","journal-title":"Protein Sci."},{"key":"4037_CR39","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1002\/cam4.4341","volume":"10","author":"Y Jin","year":"2021","unstructured":"Jin, Y. et al. Identification of novel subtypes based on SsGSEA in immune-related prognostic signature for tongue squamous cell carcinoma. Cancer Med. 10, 8693\u20138707 (2021).","journal-title":"Cancer Med."},{"key":"4037_CR40","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013).","journal-title":"Nat. Commun."},{"key":"4037_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biology (Clifton N J). 1711, 243\u2013259 (2018).","journal-title":"Methods Mol. Biology (Clifton N J)"},{"key":"4037_CR42","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher, P., Cox, N. & Huang, R. S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 9, e107468 (2014).","journal-title":"PLoS ONE"},{"key":"4037_CR43","doi-asserted-by":"publisher","first-page":"111776","DOI":"10.1016\/j.biopha.2021.111776","volume":"140","author":"A Tajbakhsh","year":"2021","unstructured":"Tajbakhsh, A. et al. The complex roles of efferocytosis in cancer development, metastasis, and treatment. Biomed. Pharmacotherapy = Biomedecine Pharmacotherapie. 140, 111776 (2021).","journal-title":"Biomed. Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"4037_CR44","doi-asserted-by":"publisher","first-page":"10496","DOI":"10.3390\/ijms231810496","volume":"23","author":"PK Biswas","year":"2022","unstructured":"Biswas, P. K. et al. TTYH3 modulates bladder Cancer proliferation and metastasis via FGFR1\/H-Ras\/A-Raf\/MEK\/ERK pathway. Int. J. Mol. Sci. 23, 10496 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"4037_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.omto.2022.08.004","volume":"26","author":"PM Chow","year":"2022","unstructured":"Chow, P. M. et al. The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma. Mol. Ther. Oncolytics. 26, 387\u2013398 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"4037_CR46","doi-asserted-by":"publisher","first-page":"963877","DOI":"10.3389\/fimmu.2022.963877","volume":"13","author":"S Pan","year":"2022","unstructured":"Pan, S. et al. Immune status for monitoring and treatment of bladder cancer. Front. Immunol. 13, 963877 (2022).","journal-title":"Front. Immunol."},{"key":"4037_CR47","doi-asserted-by":"publisher","first-page":"e30862","DOI":"10.7554\/eLife.30862","volume":"6","author":"AM Halstead","year":"2017","unstructured":"Halstead, A. M. et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife 6, e30862 (2017).","journal-title":"Elife"},{"key":"4037_CR48","doi-asserted-by":"publisher","first-page":"110743","DOI":"10.1016\/j.cellsig.2023.110743","volume":"109","author":"Z Zeng","year":"2023","unstructured":"Zeng, Z. et al. Downregulation of RAB17 have a poor prognosis in kidney renal clear cell carcinoma and its expression correlates with DNA methylation and immune infiltration. Cell. Signal. 109, 110743 (2023).","journal-title":"Cell. Signal."},{"key":"4037_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","volume":"39","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J. Exp. Clin. Cancer Res. 39, 112 (2020).","journal-title":"J. EXPERIMENTAL Clin. CANCER Res."},{"key":"4037_CR50","doi-asserted-by":"publisher","first-page":"883178","DOI":"10.3389\/fimmu.2022.883178","volume":"13","author":"JM Peng","year":"2022","unstructured":"Peng, J. M. et al. Evasion of NK cell immune surveillance via the vimentin-mediated cytoskeleton remodeling. Front. Immunol. 13, 883178 (2022).","journal-title":"Front. Immunol."},{"key":"4037_CR51","doi-asserted-by":"publisher","first-page":"596484","DOI":"10.3389\/fcell.2021.596484","volume":"9","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Immune profiling reveals molecular classification and characteristic in urothelial bladder Cancer. Front. Cell. Dev. Biol. 9, 596484 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"4037_CR52","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3389\/fonc.2019.01101","volume":"9","author":"S Pan","year":"2019","unstructured":"Pan, S., Zhan, Y., Chen, X., Wu, B. & Liu, B. Bladder Cancer exhibiting high immune infiltration shows the lowest response rate to immune checkpoint inhibitors. Front. Oncol. 9, 1101 (2019).","journal-title":"Front. Oncol."},{"key":"4037_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-022-06633-0","volume":"194","author":"M Oshi","year":"2022","unstructured":"Oshi, M. et al. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. Breast Cancer Res. Treat. 194, 231\u2013241 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"4037_CR54","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2011-10-387464","volume":"119","author":"MC Bouton","year":"2012","unstructured":"Bouton, M. C. et al. Emerging role of serpinE2\/protease nexin-1 in hemostasis and vascular biology. Blood 119, 2452\u20132457 (2012).","journal-title":"Blood"},{"key":"4037_CR55","first-page":"1928","volume":"11","author":"HW Chuang","year":"2021","unstructured":"Chuang, H. W. et al. SERPINE2 overexpression is associated with poor prognosis of urothelial carcinoma. Diagnostics (Basel Switzerland). 11, 1928 (2021).","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"4037_CR56","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/cac2.12527","volume":"44","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation. Cancer Commun. (London England). 44, 384\u2013407 (2024).","journal-title":"Cancer Commun. (London England)"},{"key":"4037_CR57","doi-asserted-by":"publisher","first-page":"e79654","DOI":"10.1371\/journal.pone.0079654","volume":"8","author":"T Kawahara","year":"2013","unstructured":"Kawahara, T. et al. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. PLoS ONE. 8, e79654 (2013).","journal-title":"PLoS ONE"},{"key":"4037_CR58","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/ijms22041821","volume":"22","author":"SN Rubtsova","year":"2021","unstructured":"Rubtsova, S. N., Zhitnyak, I. Y. & Gloushankova, N. A. Phenotypic plasticity of Cancer cells based on remodeling of the actin cytoskeleton and adhesive structures. Int. J. Mol. Sci. 22, 1821 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"4037_CR59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/s12885-023-11090-z","volume":"23","author":"PI Liang","year":"2023","unstructured":"Liang, P. I. et al. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma. BMC Cancer. 23, 599 (2023).","journal-title":"BMC Cancer"},{"key":"4037_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/molehr\/gau008","volume":"20","author":"S Goto","year":"2014","unstructured":"Goto, S. et al. Role of cathepsin E in decidual macrophage of patients with recurrent miscarriage. Mol. Hum. Reprod. 20, 454\u2013462 (2014).","journal-title":"Mol. Hum. Reprod."},{"key":"4037_CR61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12974-017-0891-9","volume":"14","author":"NP Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves, N. P. et al. Differential expression of cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. J. Neuroinflammation. 14, 115 (2017).","journal-title":"J. Neuroinflammation"},{"key":"4037_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fimmu.2017.00203","volume":"8","author":"J Mengwasser","year":"2017","unstructured":"Mengwasser, J. et al. Cathepsin E deficiency ameliorates Graft-versus-Host disease and modifies dendritic cell motility. Front. Immunol. 8, 203 (2017).","journal-title":"Front. Immunol."},{"key":"4037_CR63","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-05-0259","volume":"11","author":"PJ Wild","year":"2005","unstructured":"Wild, P. J. et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin. Cancer Res. 11, 4415\u20134429 (2005).","journal-title":"Clin. Cancer Res."},{"key":"4037_CR64","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.ajpath.2012.01.023","volume":"180","author":"N Fristrup","year":"2012","unstructured":"Fristrup, N. et al. Cathepsin E, Maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am. J. Pathol. 180, 1824\u20131834 (2012).","journal-title":"Am. J. Pathol."},{"key":"4037_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-019-1091-5","volume":"38","author":"WC Huang","year":"2019","unstructured":"Huang, W. C. et al. A novel miR-365-3p\/EHF\/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing \u03b25-integrin\/c-met signaling pathway. J. Exp. Clin. Cancer Res. 38, 89 (2019).","journal-title":"J. EXPERIMENTAL Clin. CANCER Res."},{"key":"4037_CR66","doi-asserted-by":"publisher","first-page":"e0237976","DOI":"10.1371\/journal.pone.0237976","volume":"15","author":"AA Mehus","year":"2020","unstructured":"Mehus, A. A. et al. Activation of PPAR\u03b3 and Inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS ONE. 15, e0237976 (2020).","journal-title":"PLoS ONE"},{"key":"4037_CR67","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","volume":"83","author":"J Zhuang","year":"2023","unstructured":"Zhuang, J. et al. Cancer-Associated Fibroblast-Derived miR-146a-5p generates a niche that promotes bladder Cancer stemness and chemoresistance. Cancer Res. 83, 1611\u20131627 (2023).","journal-title":"Cancer Res."},{"key":"4037_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44\u201356 (2019).","journal-title":"Ann. Oncol."},{"key":"4037_CR69","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"4037_CR70","first-page":"e2205613","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. ETV4 mediated Tumor-Associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Adv. Sci.  10, e2205613 (2023).","journal-title":"Baden-Wurttemberg Germany)"},{"key":"4037_CR71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","volume":"470","author":"X Lei","year":"2020","unstructured":"Lei, X. et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 470, 126\u2013133 (2020).","journal-title":"Cancer Lett."},{"key":"4037_CR72","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","volume":"108","author":"ME Winerdal","year":"2011","unstructured":"Winerdal, M. E. et al. FOXP3 and survival in urinary bladder cancer. BJU Int. 108, 1672\u20131678 (2011).","journal-title":"BJU Int."},{"key":"4037_CR73","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1158\/2326-6066.CIR-17-0466","volume":"6","author":"ME Winerdal","year":"2018","unstructured":"Winerdal, M. E. et al. Urinary bladder Cancer Tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol. Res. 6, 528\u2013538 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"4037_CR74","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling Inhibition for Cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 561 (2017).","journal-title":"Front. Pharmacol."},{"key":"4037_CR75","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.euo.2020.11.010","volume":"4","author":"B Szabados","year":"2021","unstructured":"Szabados, B. et al. Toxicity and surgical complication rates of neoadjuvant Atezolizumab in patients with Muscle-invasive bladder Cancer undergoing radical cystectomy: updated safety results from the ABACUS trial. Eur. Urol. Oncol. 4, 456\u2013463 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"4037_CR76","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.euo.2023.12.008","volume":"7","author":"R Li","year":"2024","unstructured":"Li, R. et al. Comparative effectiveness of neoadjuvant pembrolizumab versus Cisplatin-based chemotherapy or upfront radical cystectomy in patients with Muscle-invasive urothelial bladder Cancer. Eur. Urol. Oncol. 7, 614\u2013624 (2024).","journal-title":"Eur. Urol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04037-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:02:25Z","timestamp":1749196945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04037-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4037"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04037-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19912"}}